G5-AuNP-Gd

G5-AuNP-Gd is an experimental **nanoparticle-based imaging agent** consisting of Generation 5 poly(amidoamine) (PAMAM) dendrimer conjugated with gold nanoparticles (AuNPs) and gadolinium chelate (DOTA-Gd). This platform serves as a **dual-modal contrast agent** for both computed tomography (CT) and magnetic resonance imaging (MRI). The dendrimer acts as a scaffold to which gold nanoparticles provide X-ray attenuation for CT imaging, while gadolinium provides T1 relaxivity for MRI enhancement[1][3]. When conjugated with targeting antibodies such as Trastuzumab, the construct can specifically target HER-2 positive cancer cells, enabling targeted tumor imaging[1]. The platform has been tested preclinically in mouse models for breast cancer and lung cancer imaging, demonstrating enhanced signal intensity in both CT and MRI modalities[1]. The synthesis involves creating G5-PEG-Alkyne-DOTA-NHAc, loading it with gadolinium, and optionally conjugating targeting moieties through copper-catalyzed click chemistry[1].

Other names

G5-AuNP-Gd-Trastuzumab (when conjugated with Trastuzumab)Generation 5 PAMAM dendrimer conjugated with gold nanoparticles and DOTA-GdGeneration5 PAMAM dendrimer conjugated with gold nanoparticles and DOTA-GdGeneration-5 PAMAM dendrimer conjugated with gold nanoparticles and DOTA-Gd